Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Phase 2, Multicenter, Open-Label Clinical Study to Evaluate the Safety and Efficacy of ABSK061 and ABSK043 with or Without Chemotherapy in Patients with Metastatic/Unresectable Solid Tumors with FGFR2/3 Alterations

NCT06632262 is registered in ClinicalTrials.gov with Abbisko Therapeutics Co, Ltd as lead sponsor.

NCT NCT06632262
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06632262 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Phase 2, Multicenter, Open-Label Clinical Study to Evaluate the Safety and Efficacy of ABSK061 and ABSK043 with or Without Chemotherapy in Patients with Metastatic/Unresectable Solid Tumors with FGFR2/3 Alterations
Lead sponsor
Abbisko Therapeutics Co, Ltd
Phase
Phase 2
Overall status
Recruiting
Start date
November 13, 2024
Completion date
June 30, 2030
Enrollment
202 (estimated)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

her2-gastric/gastroesophageal junction cancer, non-small cell lung cancer, solid tumors, urothelial carcinoma